- Home
- ICCM vs AVTX Comparison
ICCM vs AVTX Comparison
Compare ICCM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- AVTX
- Stock Information
- Founded
- ICCM 2006
- AVTX 2011
- Country
- ICCM Israel
- AVTX United States
- Employees
- ICCM N/A
- AVTX N/A
- Industry
- ICCM
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- AVTX Health Care
- Exchange
- ICCM Nasdaq
- AVTX Nasdaq
- Market Cap
- ICCM 59.9M
- AVTX 57.4M
- IPO Year
- ICCM N/A
- AVTX 2015
- Fundamental
- Price
- ICCM $1.05
- AVTX $4.89
- Analyst Decision
- ICCM Strong Buy
- AVTX Strong Buy
- Analyst Count
- ICCM 1
- AVTX 7
- Target Price
- ICCM $2.50
- AVTX $31.00
- AVG Volume (30 Days)
- ICCM 361.2K
- AVTX 83.5K
- Earning Date
- ICCM 08-19-2025
- AVTX 08-11-2025
- Dividend Yield
- ICCM N/A
- AVTX N/A
- EPS Growth
- ICCM N/A
- AVTX N/A
- EPS
- ICCM N/A
- AVTX N/A
- Revenue
- ICCM $3,273,000.00
- AVTX $441,000.00
- Revenue This Year
- ICCM $83.41
- AVTX N/A
- Revenue Next Year
- ICCM $185.02
- AVTX N/A
- P/E Ratio
- ICCM N/A
- AVTX $0.71
- Revenue Growth
- ICCM 0.34
- AVTX N/A
- 52 Week Low
- ICCM $0.48
- AVTX $3.39
- 52 Week High
- ICCM $1.66
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ICCM 51.32
- AVTX 54.89
- Support Level
- ICCM $0.96
- AVTX $4.63
- Resistance Level
- ICCM $1.17
- AVTX $5.02
- Average True Range (ATR)
- ICCM 0.08
- AVTX 0.27
- MACD
- ICCM 0.01
- AVTX 0.00
- Stochastic Oscillator
- ICCM 63.89
- AVTX 72.73
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).